Nippon Life Global Investors Americas Inc. Purchases Shares of 53,400 DexCom, Inc. $DXCM

Posted by George Bondi on Aug 17th, 2026

Nippon Life Global Investors Americas Inc. purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) during the 2nd quarter, HoldingsChannel reports. The firm purchased 53,400 shares of the medical device company’s stock, valued at approximately $3,596,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. BOKF NA grew its position in shares of DexCom by 175.7% in the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock valued at $2,344,000 after buying an additional 22,505 shares during the last quarter. Stephens Investment Management Group LLC lifted its position in DexCom by 21.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock worth $69,211,000 after acquiring an additional 181,701 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in DexCom in the 4th quarter valued at $3,231,000. Goodman Advisory Group LLC purchased a new position in DexCom during the fourth quarter worth about $1,293,000. Finally, Employees Retirement System of Texas acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $37,871,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

DXCM stock opened at $89.75 on Monday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $91.96. The firm has a 50 day simple moving average of $76.08 and a 200 day simple moving average of $70.34. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The firm has a market cap of $33.87 billion, a PE ratio of 35.47, a P/E/G ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the prior year, the firm earned $0.48 EPS. The firm’s quarterly revenue was up 13.1% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on DXCM shares. Wells Fargo & Company upped their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Raymond James Financial reiterated a “strong-buy” rating and issued a $94.00 target price on shares of DexCom in a report on Friday, July 31st. JPMorgan Chase & Co. raised their price objective on DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. Finally, Mizuho lifted their price target on shares of DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $88.71.

Read Our Latest Report on DexCom

Insider Buying and Selling

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director directly owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 99,794 shares of company stock valued at $7,373,321 in the last three months. 0.28% of the stock is currently owned by corporate insiders.

About DexCom

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.